Source: Dr. Urso, Twitter

MILLION DOLLAR EARLY TREATMENT CHALLENGE. I’M NOT TOO WORRIED.

TREAT EARLY, WE CAN HELP http://AFLDS.com

video

Hey everyone, it’s Dr. Richard Urso, here to talk to you about the senate hearing, where they talked about early treatment for patients with covid. As you know, the NIH has said that we shouldn’t treat any patients early covid, and I really can’t understand why they have come to this conclusion, and I want some doctor somewhere to explain to me, and if they can explain to me why we’re not treating early I would gladly offer them a million dollars.

The disease involves infection, inflammation, blood clots and breathing problems. I want some doctor somewhere to tell me why we shouldn’t treat patients early for breathing problems, for blood clots, for inflammation. Explain that to me. We can disagree perhaps about attacking the pathogen but the disease medication, the disease tolerance, prevention, makes no sense not to try to do that early on.

So if you want to disagree on hydroxychloroquine, Ivermectin, whatever early on Remdesivir attacking the pathogen fine but explain to me somehow why you can withhold treatment for inflammation, for potential breathing problems, for blood clots. Explain that to me and I’ll give you a million dollars okay got it? I know you’re not going to do it because you’re hypocritical anyway. Bye bye.






Related:

Coronavirus and hydroxychloroquine. A cure that works, but that is not authorized …

Piedmont gives the green light to hydroxychloroquine

Ruling gives green light for controversial COVID-19 therapy

Council of State: yes to the use of hydroxychloroquine for the treatment of Covid:

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »